Histone deacetylase inhibitors in cancer therapy
10.3760/cma.j.issn.1673-422X.2011.06.008
- VernacularTitle:组蛋白脱乙酰基酶抑制剂在肿瘤治疗中的应用
- Author:
Yuanyuan LI
;
Bin ZHANG
;
Xuchen CAO
- Publication Type:Journal Article
- Keywords:
Neoplasms;
Histone deacetylases;
Biological markers
- From:
Journal of International Oncology
2011;38(6):424-427
- CountryChina
- Language:Chinese
-
Abstract:
The acetylation status of histories regulates access of transcription factors to DNA and influences levels of gene expression.Histone deacetylase(HDAC)activity diminishes acctylation of histones,causing compaction of the DNA-histone complex.This compaction blocks gene transcription and inhibits cell differentiation.HDAC inhibitom decompact the DNA-histone complex and promote cell growth arrest,differentiation,and apoptosis of tumor cells.Meantime,HDAC inhibition also affects acetylation status and function of non-histone proteins.HDAC inhibitors not only possess significant anti-tumor effects with single use,but also has great significance in combined therapy with other drugs.
